922 results match your criteria Asia-pacific Journal Of Clinical Oncology[Journal]


Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim.

Asia Pac J Clin Oncol 2019 Apr 17. Epub 2019 Apr 17.

College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea.

Aim: Neutropenia is a common side effect of myelosuppressive chemotherapy. Administration of granulocyte colony-stimulating factor is being used for neutropenia prophylaxis, but there are patients who develop neutropenia or febrile neutropenia despite prophylaxis. We attempted to identify potential risk factors for chemotherapy-induced neutropenia in patients with pegfilgrastim prophylaxis. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/ajco.13152
Publisher Site
http://dx.doi.org/10.1111/ajco.13152DOI Listing
April 2019
1 Read

Correlation between the protein expression levels of A-kinase anchor protein95, p-retinoblastoma (Ser780), cyclin D2/3, and cyclin E2 in esophageal cancer tissues.

Asia Pac J Clin Oncol 2019 Apr 16. Epub 2019 Apr 16.

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen Fujian, China.

Aim: This study aimed to investigate the correlation between the expression of A-kinase anchor protein95 (AKAP95), p-retinoblastoma (phosphorylated Rb, p-Rb), cyclin D2, cyclin D3 and cyclin E2 in esophageal cancer tissues and clinicopathological indexes.

Method: The protein expression levels of AKAP95, p-Rb, cyclin D2/3 and cyclin E2 in 40 esophageal cancer tissues were detected using immunohistochemistry, and the correlation between them was analyzed.

Result: The percentage of p-Rb (Ser780)-, cyclin D2-, cyclin D3- and cyclin E2-positive samples was 62. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13146DOI Listing
April 2019
1 Read

A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.

Asia Pac J Clin Oncol 2019 Apr 1. Epub 2019 Apr 1.

Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

Aim: We investigated the efficacy, safety and optimal schedule of nanoparticle albumin-bound paclitaxel monotherapy as second- or third-line treatment for non-small-cell lung cancer patients without epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.

Methods: Patients with pretreated advanced non-small-cell lung cancer without epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement were included. The patients were administered 100 mg/m of nanoparticle albumin-bound paclitaxel on days 1, 8, 15 and 22 (level 0) or on days 1, 8 and 15 (level -1) every 4 weeks during phase I of the trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13147DOI Listing
April 2019
3 Reads

Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer.

Asia Pac J Clin Oncol 2019 Mar 19;15 Suppl 2:5-13. Epub 2019 Mar 19.

Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, China.

Aim: To investigate treatment patterns and outcomes of metastatic colorectal cancer (mCRC) patients beyond second progression (PD2) since regorafenib and TAS-102 became available in Hong Kong.

Methods: The clinical records of consecutive mCRC patients who were treated beyond PD2 at Department of Clinical Oncology, Queen Mary Hospital between June 2013 and February 2018, were retrospectively reviewed.

Results: Of 176 PD2 patients (76. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13114DOI Listing
March 2019
1 Read

Significance of CEP78 and WDR62 gene expressions in differentiated thyroid carcinoma: Possible predictors of lateral lymph node metastasis.

Asia Pac J Clin Oncol 2019 Mar 18. Epub 2019 Mar 18.

Medical Biochemistry Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Objectives: This study aimed at investigating the clinical significance of CEP78 and WDR62 in differentiated thyroid carcinoma (DTC). This study also aimed at finding predictors that help in detecting patients with DTC who have high risk for lateral lymph node metastasis (LNM).

Methods: Quantitative real-time polymerase chain reaction (RT-qPCR) was performed to examine CEP78, and WDR62 mRNA expressions in 40 tissue specimens of DTC, and 40 goiter tissue specimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13143DOI Listing
March 2019
1 Read

A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.

Asia Pac J Clin Oncol 2019 Mar 15. Epub 2019 Mar 15.

Fudan University Shanghai Cancer Center, Shanghai, China.

Aim: To investigate the use of docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-world clinical practice in China.

Methods: This single-arm, prospective, observational study was conducted at 32 study centers in China and included male patients aged ≥18 years with histologically confirmed prostate cancer who received ≥1 dose of docetaxel following failure of hormonal therapy (disease progression with serum testosterone <50 ng/dL). The primary aim was to investigate patterns of docetaxel treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13142DOI Listing
March 2019
2 Reads

Patterns of care for stage III non-small cell lung cancer in Australia.

Asia Pac J Clin Oncol 2019 Mar 14. Epub 2019 Mar 14.

St Vincent's Hospital and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.

Stage III non-small cell lung cancer (NSCLC) makes up a third of all NSCLC cases and is potentially curable. Despite this 5-year survival rates remain between 15% and 20% with chemoradiation treatment alone given with curative intent. With the recent exciting breakthroughs in immunotherapy use (durvalumab) for stage III NSCLC, further improvements in patient survival can be expected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13140DOI Listing
March 2019
3 Reads

Utilization of stereotactic ablative radiotherapy in oligometastatic & oligoprogressive skeletal metastases: Results and pattern of failure.

Asia Pac J Clin Oncol 2019 Mar 12;15 Suppl 2:14-19. Epub 2019 Mar 12.

Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.

Aim: To evaluate the outcome and toxicities of stereotactic ablative radiotherapy (SABR) for skeletal metastasis in a tertiary cancer center.

Methods: This is a retrospective review of 22 patients treated with SABR for skeletal metastases for oligometastases (OM) or oligoprogression (OP) since October 2012. There are a total of 27 treatments with 20 spinal and seven non-spinal metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13115DOI Listing
March 2019
1 Read

Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer.

Asia Pac J Clin Oncol 2019 Mar 8. Epub 2019 Mar 8.

Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.

Aims: Participating in clinical trials could give cancer patients potential benefits such as experimental treatment, meticulous follow-up, and management of toxicities. We hypothesized that patients participating in clinical trials would achieve better survival outcomes than those not enrolled in trials. We assessed whether the trial effect can improve survival for patients with advanced gastric cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13145DOI Listing
March 2019
2 Reads

First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment.

Asia Pac J Clin Oncol 2019 Mar 6. Epub 2019 Mar 6.

Illawarra Health and Medical Research Institute, Wollongong, Australia.

Background: 5-Fluorouracil (5-FU) is administered with leucovorin (LV) to enhance clinical activity. However, simultaneous administration is not feasible due to their chemical incompatibility, so conditions for the maximum possible beneficial interaction cannot be met. To overcome this, we developed a novel all-in-one, pH neutral stable solution of 5-FU plus LV with β-cyclodextrin (termed Deflexifol) and assessed its safety and tolerability in a first-in-human phase I trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13144DOI Listing
March 2019
5 Reads

BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.

Asia Pac J Clin Oncol 2019 Mar 6;15 Suppl 2:20-31. Epub 2019 Mar 6.

Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong.

Aims: BRCA mutation (BRCAmut) testing is an important tool for the risk assessment, prevention and early diagnosis of breast cancer (BC) and ovarian cancer (OC), and more recently, for determining patient susceptibility to targeted therapy. This study assessed the current BRCAmut testing patterns and explored physicians' perspectives on the utilities and optimal sequencing of the testing, in order to facilitate and standardize testing practices.

Methods: Medical specialists in BC and OC in Hong Kong were invited to complete a questionnaire on BRCAmut testing practices. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13116
Publisher Site
http://dx.doi.org/10.1111/ajco.13116DOI Listing
March 2019
9 Reads

Immune checkpoint inhibitor use in antisynthetase syndrome.

Asia Pac J Clin Oncol 2019 Feb 27. Epub 2019 Feb 27.

Department of Respiratory Medicine, Gold Coast University Hospital, Southport, QLD, Australia.

We report on the unique case of a patient with antisynthetase syndrome and metastatic non-small cell lung cancer undergoing therapy with the PD-1 checkpoint inhibitor, nivolumab. Despite adequate autoimmune disease control over a period of 12 months, the patient rapidly experienced a flare of interstitial lung disease following initial nivolumab administration, which ultimately proved fatal. The use of immune checkpoint inhibitors in patients with autoimmune disease is becoming more commonplace, however this is the first reported case of the use of these agents in a patient with antisynthetase syndrome. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13141
Publisher Site
http://dx.doi.org/10.1111/ajco.13141DOI Listing
February 2019
4 Reads

How to conduct meta-analysis for studies with multiple intervention groups.

Asia Pac J Clin Oncol 2019 Feb 27. Epub 2019 Feb 27.

Nantong University Medicine School, Nantong, 226001, P.R. China.

In this letter, we will introduce how to conduct a correct meta-analysis for studies with multiple intervention groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13134DOI Listing
February 2019
1.058 Impact Factor

Reply to Q. Wu et al.

Asia Pac J Clin Oncol 2019 Feb 27. Epub 2019 Feb 27.

Cancer Care Centre, St George Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13132DOI Listing
February 2019
5 Reads

Combined immune therapy grade IV dermatitis in metastatic melanoma.

Asia Pac J Clin Oncol 2019 Feb 27. Epub 2019 Feb 27.

Department of Medical Oncology, The Canberra Hospital, Garran, Australian Capital Territory, Australia.

Checkpoint inhibition is the mainstay of treatment in metastatic melanoma. More recently combined cytotoxic T-lymphocyte antigen-4 and programmed-death-1 blockade has resulted in improved response rates and overall survival in treatment naïve patients compared to monotherapy albeit with increased rates of adverse events. Dermatologic toxicities are an emerging consequence of the use of checkpoint inhibitors and have reportedly been more prevalent with the use of combined therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13136DOI Listing
February 2019
2 Reads
1.058 Impact Factor

Allium vegetables are associated with reduced risk of colorectal cancer: A hospital-based matched case-control study in China.

Asia Pac J Clin Oncol 2019 Feb 20. Epub 2019 Feb 20.

Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.

Aim: The present study aimed to investigate and identify the association between the intake of allium vegetables and colorectal cancer (CRC) in population.

Methods: A hospital-based matched case-control study was conducted between June 2009 and November 2011 in three hospitals. Eight hundred thirty three consecutively recruited cases of CRC were frequency matched to 833 controls by age (within 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13133DOI Listing
February 2019

Docetaxel therapy for classic Kaposi's sarcoma.

Asia Pac J Clin Oncol 2019 Feb 21. Epub 2019 Feb 21.

Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13139DOI Listing
February 2019

The diameter of metastasis in positive sentinel lymph node biopsy affects axillary tumor load in early breast cancer.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Pathology Department, West Pomeranian Oncology Center, Szczecin, Poland.

Introduction: Omission of axillary lymph node dissection (ALND) after positive sentinel lymph biopsy (SLNB) has become a standard procedure for breast cancer patients with one or two metastatic lymph nodes. Here the aim was model development for selection for ALND.

Material And Methods: We analyzed 323 positive SLNB breast cancer patients, who afterwards underwent ALND. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13113DOI Listing
February 2019

Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Footscray Hospital, Western Health, Footscray, Victoria, Australia.

Background: Metastatic colorectal cancer (mCRC) patients with a right-sided primary (RC) have an inferior survival to mCRC arising from a left-sided primary (LC). Previous analyses have suggested multiple factors contribute.

Methods: The Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) Registry prospectively captured data on consecutive mCRC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13135DOI Listing
February 2019
1 Read
1.058 Impact Factor

Translation and psychometric testing of Cancer Survivors' Unmet Needs, Chinese version.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

School of Nursing, Queensland University of Technology, Brisbane, Queensland, Australia.

Aim: The aim of the study was to translate the Cancer Survivors' Unmet Needs (CaSUN) scale into Chinese, and then test its psychometric properties, for cancer survivors in Hong Kong.

Methods: The original questionnaire was translated from English into traditional Chinese (CaSUN-Chi), following standardized procedures. An expert panel was invited to assess the items' content validity, and pilot test on 15 patients to evaluate its readability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13137DOI Listing
February 2019
2 Reads
1.058 Impact Factor

Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Centre of Systems Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Aim: There is no consensus regarding the association between hormone replacement therapy (HRT) and risk of meningioma so far. We conducted the first study among Chinese female patients to investigate the influence of HRT use on the risk of meningioma.

Methods: We retrospectively collected records of diagnosis of meningioma for women aged 50 years and above during 2011-2016 and dispense of HRT prior to meningioma diagnosis in three tertiary hospitals in China. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13138
Publisher Site
http://dx.doi.org/10.1111/ajco.13138DOI Listing
February 2019
12 Reads

Patterns of follow-up care after curative radiotherapy ± chemotherapy for stage I-III non-small cell lung cancer.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

South Western Sydney Clinical School, University of NSW, NSW, Australia.

Objectives: To describe patterns of follow-up care for non-small cell lung cancer patients treated with curative radiotherapy and to evaluate the role of routine imaging.

Materials And Methods: We retrospectively analyzed follow-up care of patients with stage I-III non-small cell lung cancer treated with curative radiotherapy (minimum dose of 50 Gy) between 2007 and 2011 at three Sydney institutions. Patient demographics, tumor characteristics and treatment factors were collected from oncology and hospital records. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13127DOI Listing
February 2019
4 Reads

First-line therapy for metastatic colorectal cancer: Current perspectives and future directions.

Asia Pac J Clin Oncol 2019 Feb;15 Suppl 1:3-14

Department of Cancer Care Services, Royal Brisbane Hospital, University Of Queensland, Herston, Queensland.

The prognosis for patients with newly diagnosed inoperable metastatic colorectal cancer has steadily improved over the past two decades as new agents have been introduced into clinical practice and many new biomarkers have been discovered. In parallel with this progress, clinicians face increasingly complex treatment decisions. This review summarizes recent progress, with a historical perspective, which should help guide the clinician in decision making and optimal therapy selection. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13119
Publisher Site
http://dx.doi.org/10.1111/ajco.13119DOI Listing
February 2019
4 Reads
1.058 Impact Factor

Registry-based randomized clinical trials as a method to improve cancer care in Australia.

Asia Pac J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Systems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13122DOI Listing
February 2019
1.058 Impact Factor

Embracing the full spectrum of real-world data for cancer medicines research in Australia.

Asia Pac J Clin Oncol 2019 Feb 12. Epub 2019 Feb 12.

Centre for Big Data Research in Health, University of New South Wales, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13121
Publisher Site
http://dx.doi.org/10.1111/ajco.13121DOI Listing
February 2019
1 Read

What contributes to resilience in cancer patients? A principal component analysis of the Connor-Davidson Resilience Scale.

Asia Pac J Clin Oncol 2019 Feb 11. Epub 2019 Feb 11.

Flinders Centre for Innovation in Cancer, Flinders Medical Centre, and Flinders University, Adelaide, South Australia, Australia.

Purpose: Research suggests resilience is a complex multifactorial construct, which may improve health outcomes in cancer, but significant controversy exists regarding its definition and measurement. This study aimed to determine the components of resilience and their relative weight, as measured by the Connor-Davidson Resilience Scale in cancer patients.

Methods: As part of a larger study, a questionnaire including the Connor-Davidson Resilience Scale was distributed to 228 cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13128DOI Listing
February 2019
1.058 Impact Factor

Association between human papillomavirus infection and prostate cancer: A global systematic review and meta-analysis.

Asia Pac J Clin Oncol 2019 Feb 10. Epub 2019 Feb 10.

Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Although an increasing number of studies have been conducted to evaluate the association between human papillomavirus (HPV) infections and distribution of HPV types worldwide with the risk of prostate cancer (PC), the results remain inadequate. Hence, we investigated the association between HPV infection and PC risk using a meta-analysis. Relevant studies from January 1990 to December 2016 were searched in PubMed, Web of sciences, and Scopus databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13124DOI Listing
February 2019
1 Read
1.058 Impact Factor

Significance of methylation status of MASPIN gene and its protein expression in prognosis of gallbladder cancer.

Asia Pac J Clin Oncol 2019 Feb 10. Epub 2019 Feb 10.

Department of Orthopaedic Surgery, King George's Medical University, Lucknow, India.

Aim: We investigated prognostic significance of methylation status of MASPIN gene and its protein expression in normal subjects, cholelithiasis and gallbladder cancer (GBC) patients.

Methods: MASPIN protein expression and its promoter methylation in gallbladder tissue of cholelithiasis (n = 36), GBC (n = 46) and controls (n = 25) were investigated. Clinicopathological parameters and prognosis of patients with GBC were correlated with protein expression of MASPIN. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13129DOI Listing
February 2019
1 Read
1.058 Impact Factor

Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers.

Asia Pac J Clin Oncol 2019 Feb 6. Epub 2019 Feb 6.

Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center of China, Beijing, China.

Men with prostate cancer with positive margins, extraprostatic extension, positive lymph nodes, high prostate-specific antigen, or high Gleason Score are at high risk of recurrence following primary therapy. Androgen deprivation therapy (ADT), which includes medical/surgical castration, antiandrogen therapy, and combined androgen blockade, can be combined with primary therapy to shrink the tumor, reduce margin positivity, and reduce the risk of recurrence. However, many problems still remain, such as optimizing the application of ADT in the treatment of prostate cancer, for example, ideal patient population and optimal timing and duration of therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13108DOI Listing
February 2019
1 Read

Reply to M. Alexander et al.

Asia Pac J Clin Oncol 2019 Feb 3. Epub 2019 Feb 3.

Section of Thrombosis & Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13098DOI Listing
February 2019
1.058 Impact Factor

Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.

Asia Pac J Clin Oncol 2019 Jan 30. Epub 2019 Jan 30.

Olivia Newton-John Cancer Wellness & Research Centre, Austin Hospital, Melbourne, Victoria, Australia.

Aim: Targeted therapy (TT) has improved survival for metastatic renal cell carcinoma (mRCC). However, survival is usually limited if brain metastases (BMs) develop. We aimed to evaluate survival outcomes in mRCC patients based on timing of BM diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13109DOI Listing
January 2019
4 Reads

Hurdles in radiation planning for glioblastoma: Can delayed-contrast enhanced computed tomography be a potential solution?

Asia Pac J Clin Oncol 2019 Jan 30. Epub 2019 Jan 30.

Department of Radiotherapy, PGIMER, Chandigarh, India.

Objective: Conformal radiation is the standard of care in treatment of glioblastoma. Although co-registration of magnetic resonance imaging (MRI) with early contrast enhanced computed tomography (CECT) is recommended for target delineation by consensus guidelines, ground realities in developing countries often result in availability of less-than-ideal MR sequences for treatment planning. Purpose of this study is to analyze the impact of incorporation of delayed-CECT sequences for radiation planning in glioblastomas, as an adjunct or alternative to MRI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13111DOI Listing
January 2019
2 Reads

Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.

Asia Pac J Clin Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Purpose: Lung cancer with malignant peritoneal carcinomatosis and malignant ascites is rare, often indicates the terminal stage, and is refractory to treatment. The median survival time of lung cancer patients with malignant ascites has been reported to be as short as 15 days to 2 months in retrospective studies.

Methods: We reviewed all lung cancer patients who had cytologically or pathologically proven malignant ascites and received aggressive therapy including chemotherapy, anti-angiogenesis agents and target therapy at a Taiwan hospital from January 2015 to December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13131DOI Listing
January 2019
2 Reads

Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.

Asia Pac J Clin Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Aims: Metastatic colorectal cancer (mCRC) with deficient DNA mismatch repair (dMMR) is a rare disease accounting only for 4-5% of the whole mCRC and its optimal treatment still remains unclear. We conducted a retrospective study to evaluate the outcome of chemotherapy with or without bevacizumab or cetuximab in this setting.

Methods: A total of 729 colorectal cancer patients with dMMR status were screened for eligibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13130DOI Listing
January 2019
1.058 Impact Factor

Association of APOBEC3 deletion with cancer risk: A meta-analysis of 26 225 cases and 37 201 controls.

Asia Pac J Clin Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Genetics, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran.

Previous studies have found inconsistent results regarding gene deletion in APOBEC3 (apolipoprotein B mRNA-editing catalytic polypeptide-like 3) and risk of cancer. We conducted a meta-analysis of all eligible case-control studies to find out the associations between APOBEC3 deletion and cancer risk by pooling the odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Overall, the findings from 20 studies (13 articles) involving of a total of 26 225 cases and 37 201 controls revealed that DD genotype was associated significantly with increased cancer risk compared to II genotype (OR = 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13107DOI Listing
January 2019

Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma.

Asia Pac J Clin Oncol 2019 Jan 10. Epub 2019 Jan 10.

Department of Surgery, Meiwa Hospital, Hyogo, Japan.

Aim: Systemic inflammation and nutritional status are associated with clinical outcomes of cancer patients. We investigated the prognostic value of preoperative C-reactive protein to albumin ratio (CAR) in patients with pancreatic ductal adenocarcinoma (PDA) after pancreatic resection.

Methods: One-hundred and thirty-six PDA patients who underwent pancreatic resection between January 2005 and June 2017 were retrospectively enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13123DOI Listing
January 2019
1 Read

The value of magnetic resonance imaging in esophageal carcinoma: Tool or toy?

Asia Pac J Clin Oncol 2019 Jan 4. Epub 2019 Jan 4.

Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, Shandong Province, China.

Currently, the use of magnetic resonance imaging (MRI) in patients with esophageal carcinoma is limited. However, the quality of MRI for esophageal carcinoma continues to improve and the importance of MRI in patients with esophageal carcinoma has been gradually recognized. Compared with endoscopic ultrasound and computed tomography applied in T and N staging, MRI has now achieved excellent results after the imaging technique has been optimized. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13112DOI Listing
January 2019
3 Reads

Impact of modified FOLFOX-6 for patients with gastric cancer and a gastrointestinal obstruction.

Asia Pac J Clin Oncol 2018 Dec 13. Epub 2018 Dec 13.

Department of Internal Medicine II, Osaka Medical College, Takatsuki, Osaka, Japan.

Aim: Gastric cancer patients are normally treated with oral fluoropyrimidine and cisplatin or oxaliplatin; however, treating patients who also have a gastrointestinal obstruction is often difficult because of their poor oral intake. Instead, a modified (m)FOLFOX-6 regimen is administered, even to patients with gastrointestinal obstructions. The aim of this study was to assess the efficacy of mFOLFOX-6 for gastric cancer patients with a gastrointestinal obstruction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13110DOI Listing
December 2018
1 Read

A clinical trial with protracted infusion 5-fluorouracil and mitomycin C for localized squamous cell carcinoma of the anus.

Asia Pac J Clin Oncol 2019 Feb 9;15(1):75-81. Epub 2018 Dec 9.

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Purpose: Mitomycin C (MMC) plus standard 5-fluorouracil (FU) infusion in weeks 1 and 5 often contributes to radiotherapy interruptions and possibly less-than-ideal outcomes in anal cancer. This study was to evaluate alternative strategies for chemotherapy delivery that might be less toxic or more efficacious, and outcomes of patient-initiated treatment interruption for severe acute toxicity.

Materials And Methods: This was a prospective, nonrandomized study for patients with T1-4N0-3M0 anal squamous carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13106DOI Listing
February 2019
11 Reads

The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.

Asia Pac J Clin Oncol 2018 Dec 2. Epub 2018 Dec 2.

Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan.

Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used to treat patients with non-small cell lung cancer (NSCLC) and EGFR driver mutations. Although some patients discontinued these treatments because of adverse events, it is unclear whether switching EGFR-TKI because of adverse events provides a benefit.

Methods: This retrospective study evaluated data from 22 patients with EGFR mutation-positive NSCLC who received at least two EGFR-TKIs that were switched because of adverse events (March 2011 to September 2017). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13103DOI Listing
December 2018
3 Reads

Adjuvant therapy after nephrectomy for renal cell carcinoma.

Authors:
Alain Ravaud

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:33-36

Department of Medical Oncology, Hôpital Saint-André, Bordeaux, France.

Adjuvant treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor in renal cell carcinoma after nephrectomy has been reported through three clinical trials: S-TRAC, ASSURE and PROTECT. Only S-TRAC has been significantly positive on primary end-point disease-free survival under sunitinib compared to placebo, whereas ASSURE and PROTECT did not show any gain under sunitinib, sorafenib or pazopanib. This short review presents the differences between the trials and provides hypotheses on why S-TRAC may have been positive. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13056
Publisher Site
http://dx.doi.org/10.1111/ajco.13056DOI Listing
November 2018
14 Reads

Advanced prostate cancer update 2018.

Authors:
Oliver Sartor

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:9-12

Tulane Cancer Center, New Orleans, LA, USA.

The management of advanced prostate cancer today follows a multidisciplinary approach and involves multi-target treatments. The paradigm has shifted from traditional hormonal therapy, surgery and radiation, to the use of chemotherapy, and until recently the development of various immunotherapies and radiopharmaceuticals. Recent advances turn to molecular medicine combining the expertise of molecular pathology and genetics. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13057
Publisher Site
http://dx.doi.org/10.1111/ajco.13057DOI Listing
November 2018
25 Reads

Editorial.

Authors:

Asia Pac J Clin Oncol 2018 11;14 Suppl 5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13105DOI Listing
November 2018
2 Reads

Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective.

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:5-8

Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.

The treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been rapidly evolving. In the past, the use of chemotherapy was reserved for metastatic prostate cancer patients who developed castration resistance. Subsequently, there were three well-designed randomized controlled trials investigating the use of chemotherapy together with androgen deprivation therapy as the first-line treatment for metastatic hormone-sensitive prostate cancer. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13060
Publisher Site
http://dx.doi.org/10.1111/ajco.13060DOI Listing
November 2018
17 Reads

Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.

Authors:
Junpei Iizuka

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:16-23

Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Radium-223 is a first-in-class targeted alpha therapy indicated for treating bone metastases from metastatic castration-resistant prostate cancer (mCRPC) without visceral metastases. Imaging plays an important role in the selection of patients eligible for radium-223 therapy. In the ALSYMPCA trial protocol, bone scintigraphy was used to detect lesions, essentially osteoblastic bone metastases, whereas computed tomography (CT) was used to exclude visceral metastases, with no interim imaging until treatment completion unless clinically indicated. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13058
Publisher Site
http://dx.doi.org/10.1111/ajco.13058DOI Listing
November 2018
19 Reads

Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.

Authors:
Foon-Yiu Cheung

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:13-15

Hong Kong Integrated Oncology Centre, Central, Hong Kong.

Bone metastases are a hallmark of advanced prostate cancer and may drive the morbidity and mortality of the disease in patients with a poor prognosis. The pathogenesis of bone metastasis involves the interaction between cancer cells, normal bone cells and the bone microenvironment. Targeting the bone microenvironment has become a promising therapy for patients with advanced prostate cancer and bone metastasis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13061
Publisher Site
http://dx.doi.org/10.1111/ajco.13061DOI Listing
November 2018
15 Reads

Prime time for immunotherapy in advanced urothelial cancer.

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:24-32

Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario.

Background: Metastatic urothelial cancer (UC) is a lethal disease. Until 2016, cytotoxic chemotherapy with substantial toxicity was the only therapeutic option. In the first-line metastatic setting, cisplatin-based combination chemotherapy remains the standard of care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13059DOI Listing
November 2018
3 Reads

Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib.

Asia Pac J Clin Oncol 2018 Dec 26;14(6):459-464. Epub 2018 Nov 26.

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Purpose: Olaparib was originally formulated as 50 mg capsules with a recommended dose of 400 mg twice daily which requires patients to take 16 capsules a day. More recently, a tablet formulation with equivalent efficacy has become available and reduces the pill burden for patients to two tablets twice daily which is more convenient for patients. However, it is important to understand the key differences between the olaparib capsule and tablet formulations as they are not bioequivalent, and the doses are not interchangeable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13104DOI Listing
December 2018
2 Reads

Receipt of radiotherapy after mastectomy in women with breast cancer: Population-based cohort study in New Zealand.

Asia Pac J Clin Oncol 2018 Nov 15. Epub 2018 Nov 15.

Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand.

Purpose: To investigate the receipt of postmastectomy radiotherapy (PMRT) in breast cancer patients in New Zealand for whom radiotherapy is strongly recommended in current clinical guidelines.

Method: This study involved all women who were diagnosed with primary invasive breast cancer in two health regions, had undergone a mastectomy, and met the "strong recommendation" criteria for PMRT based on New Zealand National Guidelines. We performed logistic regression analyses to identify demographic and clinical factors associated with the receipt of PMRT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13101DOI Listing
November 2018
6 Reads

The potential "additive" thromboembolic risk of radiotherapy.

Asia Pac J Clin Oncol 2018 Nov 13. Epub 2018 Nov 13.

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13099
Publisher Site
http://dx.doi.org/10.1111/ajco.13099DOI Listing
November 2018
15 Reads